Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gimatecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | GLA | P06280 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gimatecan SCHEMBL24685122 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL15341182 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL1649254 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL130586 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| Gimatecan SCHEMBL27721325 | 1.00 | TOP1 (0.79) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL3181051 | 0.93 | TOP1 (0.76) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL25932531 | 0.92 | TOP1 (0.68) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL22843988 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2028767 | 0.92 | TOP1 (0.81) | TOP1ALDH1A1GLAMEN1KMT2A | |
| SCHEMBL2028388 | 0.92 | TOP1 (0.85) | TOP1ALDH1A1GLAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2383 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743122-A1 | THERAPEUTIC SEALANTS BASED UPON DRUG CONJUGATES | The Johns Hopkins University (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4739310-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) INHIBITOR COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090139-A1 | ANTI-LY6K ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NORMUNITY, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4732850-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Antelope Therapeutics SAS (FR) | 2026-04-29 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| EP-4687999-A1 | TROP2 CONJUGATED BIOLOGICAL MOLECULES, PHARMACEUTICAL COMPOSITIONS AND METHODS | OBI Pharma, Inc. (TW) | 2026-02-11 | — | — | EP | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4676544-A1 | ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODIES AGAINST HUMAN L1CAM AND USES THEREOF | LigaChem Biosciences Inc. (KR) | 2026-01-14 | — | — | EP | claimed |
| EP-4663205-A1 | POLYMER-DRUG CONJUGATE, INTERMEDIATE THEREOF, AND USE THEREOF | Shanghai Best-Link Bioscience, LLC (CN) | 2025-12-17 | — | — | EP | claimed |
| EP-3997093-A1 | PEPTIDE CONJUGATES OF CYTOTOXINS AS THERAPEUTICS | Cybrexa 2, Inc. (US) | 2022-05-18 | — | — | EP | claimed |
| US-20220135982-A1 | COMPOSITIONS FOR SUPPRESSING TRIM28 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-05 | — | — | US | claimed |
| WO-2022078279-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | 昆山新蕴达生物科技有限公司 | 2022-04-21 | — | — | WO | claimed |
| WO-2022074649-A1 | TREATMENT OF SKIN DISEASES | ICHILOV TECH LTD. (IL) | 2022-04-14 | — | — | WO | claimed |
| CN-114341162-A | Peptide conjugates of cytotoxins as therapeutic agents | 赛博克萨2公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220089570-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2022-03-24 | — | — | US | claimed |
| US-11266677-B2 | Methods for treatment or prevention of leukemia | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-03-08 | — | — | US | claimed |
| CN-114072178-A | Programmable polymeric pharmaceuticals | 索尼集团公司 | 2022-02-18 | — | — | CN | claimed |
| EP-3952917-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-02-16 | — | — | EP | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |